{"nctId":"NCT01518517","briefTitle":"GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia","startDateStruct":{"date":"2009-12","type":"ACTUAL"},"conditions":["Acute Lymphoblastic Leukemia, in Relapse"],"count":85,"armGroups":[{"label":"GRASPA","type":"EXPERIMENTAL","interventionNames":["Drug: GRASPA"]},{"label":"reference L-asparaginase","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: L-asparaginase"]}],"interventions":[{"name":"GRASPA","otherNames":["ERY001"]},{"name":"L-asparaginase","otherNames":["KIDROLASE"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient from 1 to 55 years old (Children and adolescents from 1 to 17 years/ Adults from 18 to 55 years)\n* Patients with 1st ALL relapse, which could be either isolated bone marrow relapse, or combined (medullary and extra-medullary) relapse, or extra-medullary isolated relapse; or lymphoblastic lymphoma (excepted Burkitt lymphoma) OR Failure to ALL first line treatment (no complete remission obtained)\n* Patient previously treated with free E.Coli L-asparaginase form or pegylated one\n* Performance Status â‰¤ 2 (WHO score)\n* Patient informed and consent provided (the 2 parents need to consent when children are below 18)\n\nExclusion Criteria:\n\n* ALL t(9;22) and/or BCR-ABL positive (Philadelphia chromosome positive)\n* Patient with 2nd relapse and over\n* Women of childbearing potential without effective contraception as well as pregnant or breast feeding women\n* Patient unable to receive treatments used in global chemotherapy protocols, due to general or visceral conditions such as:Severe cardiac impairment (NYHA grade 3 or 4 cardiomyopathy)/Serum creatinine 2 x ULN unless related to ALL /ALT or AST 5 x ULN unless related to ALL /Pancreatitis history /Other malignancy that ALL / Severe Infection, HIV positive, active hepatitis related to B or C virus infection / Trisomy 21 / Other serious conditions according to investigator's opinion\n* Known grade 4 allergic reaction to E.Coli L-asparaginase (according NCI-CTCAE, Version 3.0)\n* History of grade 3 transfusional incident\n* Presence of specific anti-erythrocyte antibodies preventing from getting a compatible erythrocyte concentrate for the patient\n* Patient under concomitant treatment likely to cause hemolysis\n* Patient undergoing yellow fever vaccination\n* Patient under phenytoin treatment\n* Patient included in previous clinical study less than 6 weeks ago","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"55 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Duration of Asparaginase Activity >100 U/L During Induction","description":"Co-primary efficacy endpoint: duration in days of asparaginase activity \\>100 U/L in whole blood during the induction treatment phase: last available date/time of activity \\>100 UI/L before activity drops below 100 U/L - date/time of first activity \\>100 UI/L. Asparaginase activity is compared for GRASPA versus native ASNase to demonstrate the non-inferiority of GRASPA.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.9","spread":null},{"groupId":"OG001","value":"8.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Allergic Reaction During Induction Phase","description":"Co-primary safety endpoint: allergic reaction regardless of grade during induction phase. Only those reactions that were reported in relation to the treatment to which the patient was randomised were counted.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Remission (CR)","description":"CR is defined as, no physical evidence of leukemia, normal CBC, cytologic remission: normally regenerating bone marrow, with \\<5% leukemic blasts and the absence of detectable CNS or extramedullary disease, evaluated with physical examination and CSF findings, at the end of induction","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS is defined as the time from randomisation or date of inclusion (allergic arm) until death due to any cause. Patients who did not die were censored at 36 months of follow-up or the date of the patient's last visit, whichever was earlier.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Event Free Survival","description":"EFS is defined as the time from randomisation until the first documented sign of disease relapse or death due to any cause. In line with CHMP guidance (CHMP, 2016), patients who did not achieve CR at the end of the induction period were considered to have had an event at time 0. For the patients enrolled in the GRASPA allergic arm, EFS is defined from the date of inclusion in the study.\n\nPatients who achieved CR at the end of induction and who did not have a documented relapse or death due to any cause were censored at 36 months of follow-up or the date of the patient's last visit, whichever was earlier.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":23,"n":26},"commonTop":["Leukopenia","Neutropenia","Thrombocytopenia","Lymphopenia","Transaminases increased"]}}}